

## For fourth year in a row, Elekta's Leksell Gamma Knife Perfexion earns top rank in 2014's Best in KLAS for Radiation Therapy

ATLANTA, August 7 – Elekta's <u>Leksell Gamma Knife® Perfexion™</u> radiosurgery system took the first place ranking for the fourth consecutive year in KLAS research firm's recently released *2014 Best in KLAS Awards: Medical & Infrastructure report*\*. In addition, Elekta's Agility™ 160-leaf multi-leaf collimator (MLC) and Elekta Infinity™ radiation treatment system earned second and third place.

In the report, Perfexion scored 94.5 out of 100 on the system's functionality and upgrade capacity. Perfexion also scored between 90.5 and 93.5 on four other performance categories, including service and support, and implementation and training.

"Virtually all of our Leksell Gamma Knife sites also have access to linacs for radiosurgery," says Jay Hoey, Executive Vice President, Elekta North America. "We feel the KLAS study highlights the fact that, when it comes to brain radiosurgery, the clear preference is for Gamma Knife. Gamma Knife centers appreciate the system's high efficiency, uptime and unparalleled clinical capability. We are honored by their recognition."

Further documenting the superior dosimetric performance of Perfexion, a recent multicenter study¹ showed that the system offers dramatically lower radiation dose to normal brain – in the treatment of multiple metastases – than other systems, such as Varian's TrueBeam™ flattening filter-free linear accelerator with a 2.5 mm MLC. Patients with multiple metastases, the report said, stand to receive as much as a 74 percent lower radiation dose to normal brain tissues if the lesions are treated with Perfexion versus contemporary linear accelerator-based stereotactic (SRS) systems.

## KLAS surveys include opinions of thousands of health care professionals

The KLAS awards are based on data from customer surveys of hospital and clinic executives, administrators, physicians, nurses and other directors and managers interacting with health care equipment and infrastructure solutions.

According to KLAS, Best in KLAS designations go to solutions that have excelled in their respective market segments, that show the vendor's leadership in working with customers to resolve issues and match expectations to reality, and that have the broadest operational and clinical impact to health care organizations.

The Best in KLAS designation recognizes vendors for their outstanding efforts to help healthcare professionals deliver better patient care. This award is reserved for those that lead the imaging equipment segments with the broadest operational and clinical impact on healthcare organizations.

"This is a tremendous achievement because each of the top performers earned this recognition through the voice of their provider customers," says Matt Terry, vice president of medical equipment and imaging research for KLAS. "Given that vendors must concern themselves with the complexities of a dynamic health care market and operational challenges, it is remarkable to see so many undeviating from their focus on helping providers succeed."

\*2014 Best in KLAS Award: Medical Equipment & Infrastructure, July 2014. © 2014 KLAS Enterprises, LLC. All rights reserved. <a href="www.KLASresearch.com">www.KLASresearch.com</a> http://www.klasresearch.com/klasreports/



1. Ma L, Nichol A, Hossain S, et al. (2014) Variable dose interplay effects across radiosurgical apparatus in treating multiple brain metastases. Int J CARS. Published online: 20 April 2014. doi:10.1007/s11548-014-1001-4

###

## For further information, please contact:

Gert van Santen, Group Vice President Corporate Communications, Elekta AB

Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com

Time zone: CET: Central European Time

Raven Canzeri, Global Public Relations Manager, Elekta Tel: +1 770-670-2524, e-mail: raven.canzeri@elekta.com

Time zone: ET: Eastern Time

## **About Elekta**

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO:EKTAB. Website: www.elekta.com.